Advances in incretin therapy: dual agonists and beyond With Prof. Filip Knop

This year saw the regulatory approval of the first dual GIP/GLP-1 dual agonist for type 2 diabetes. With several other multi-agonists in development, what does this mean for clinicians caring for people with type 2 diabetes? Join Prof. Filip Knop for an overview of these new and emerging agents. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at , where you can find all past episodes of the podcast as well as other free CME resources. References available here Disclosures: Prof. Filip Knop declares the following financial relationships from the past 24 months: Honorarium recipient: AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi Speakers Bureau: AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi Consultant (Occasional): AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi Advisor or Review Panel member: Eli Lilly, Novo Nordisk, Sanofi Discussion of Off-Label, Investigational, or Experimental Drug Use: None Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

You can listen to Advances in incretin therapy: dual agonists and beyond With Prof. Filip Knop online on Radio and Podcast. Open the player on this page to stream the available audio.

Advances in incretin therapy: dual agonists and beyond With Prof. Filip Knop is an episode from Diabetes Knowledge into Practice Podcast by Liberum IME.

This episode is 00:16:51 long.

This episode was published on Jul 15, 2022.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Diabetes Knowledge into Practice Podcast when more episodes are available from the podcast feed.